NCT05390164

Brief Summary

This work aims to assess sensory symptoms in early active vitiligo patients (segmental, non-segmental, or mixed) and to measure 3 neuropeptides expression in their lesional skin \[neuropeptide Y(NPY), calcitonin gene-related peptide (CGRP), and nerve growth factors (NGF)\] to correlate neuropeptide levels, sensory symptoms, and functions, with criteria of disease activity and perceived stress scale.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2022

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 20, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 25, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

May 25, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 15, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 15, 2022

Completed
Last Updated

May 25, 2022

Status Verified

May 1, 2022

Enrollment Period

3 months

First QC Date

May 20, 2022

Last Update Submit

May 20, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Neuropeptide

    laboratory test

    3 months

Study Arms (2)

Active vitiligo

Diagnostic Test: skin biopsy

Stable vitiligo

Diagnostic Test: skin biopsy

Interventions

skin biopsyDIAGNOSTIC_TEST

skin biopsy to be analyzed by ELISA

Active vitiligoStable vitiligo

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Active vitiligo patients

You may qualify if:

  • Active and stable vitiligo

You may not qualify if:

  • Diabetic or other associated disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • El Sayed H, El Wakeel H, Nour Z, Mohyeeldeen R, Hafez V. Sensory Symptoms as an Early Manifestation of Active Vitiligo: A Case-Control Clinical and Molecular Study. Pigment Cell Melanoma Res. 2025 Jan;38(1):e13223. doi: 10.1111/pcmr.13223.

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

May 20, 2022

First Posted

May 25, 2022

Study Start

May 25, 2022

Primary Completion

August 15, 2022

Study Completion

August 15, 2022

Last Updated

May 25, 2022

Record last verified: 2022-05